Immunic (NASDAQ:IMUX) Posts Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Immunic (NASDAQ:IMUX – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.20), FiscalAI reports.

Immunic Stock Performance

Shares of NASDAQ IMUX traded down $0.27 during trading on Friday, hitting $7.52. The company had a trading volume of 105,145 shares, compared to its average volume of 283,926. Immunic has a 52 week low of $5.06 and a 52 week high of $17.43. The business’s 50-day moving average is $8.70 and its 200 day moving average is $11.52. The company has a market cap of $102.57 million, a P/E ratio of -1.72 and a beta of 1.48.

Key Headlines Impacting Immunic

Here are a few of the latest headlines about IMUX:

Analysts Set New Price Targets

IMUX has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, August 26th. Wall Street Zen cut Immunic from a “sell” rating to a “strong sell” rating in a research report on Saturday. Cantor Fitzgerald started coverage on Immunic in a report on Friday, October 23rd. They issued an “overweight” rating for the company. Roth Capital reaffirmed a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Finally, Wedbush reaffirmed an “outperform” rating and set a $45.00 target price on shares of Immunic in a report on Thursday, September 10th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.43.

Get Our Latest Stock Analysis on Immunic

About Immunic

(Get Free Report)

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.

Read More

Earnings History for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.